retatrutide gip glp-1 glucagon receptor agonist peptide for weight loss and fat burning Retatrutide is drawing major attention

You should discuss these factors with your Affinity medical provider before beginning treatment

Learn more now

de Mesquita YLL et al

Improved insulin sensitivity allows better regulation of lipid metabolism

tirzepatide is a dual agonist (GIP/GLP-1) Peak weight loss : Retatrutide showed 28.7% at 68 weeks (Phase 3 TRIUMPH-4) and 24.2% at 48 weeks (Phase 2) vs tirzepatide 20.9% (Phase 3) Liver fat : Retatrutide's glucagon agonism provides pronounced hepatic fat reduction (up to 82%) Regulatory status : Tirzepatide is FDA-approved

The most common adverse effects are gastrointestinal and include nausea, vomiting, diarrhea, constipation, and abdominal pain